Related Experiment Video

Updated: Aug 16, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

[Peroxide modification of low density lipoproteins in ischemic heart disease]

A S Kuznetsov, N S Parfenova, A D Denisenko

    Ukrainskii Biokhimicheskii Zhurnal (1978)
    |May 1, 1989
    PubMed

    Insights

    Patients with ischemic heart disease have significantly higher levels of LDL peroxide lipids. This suggests pre-existing LDL modification in blood flow contributes to disease progression, even with normal macrophage uptake.

    Area of Science:

    • Biochemistry
    • Cardiovascular Medicine
    • Lipid Metabolism

    Context:

    • Ischemic heart disease (IHD) is a major global health concern.
    • Lipid peroxidation plays a critical role in cardiovascular pathology.
    • Understanding LDL modification is key to IHD pathogenesis.

    Purpose:

    • To investigate the levels of LDL peroxide lipid products in IHD patients.
    • To compare LDL uptake by macrophages in IHD patients versus healthy subjects.
    • To elucidate the role of LDL premodification in IHD.

    Summary:

    • LDL peroxide lipid products were found to be 1.6-4 times higher in IHD patients compared to normal subjects.
    • Macrophage uptake of LDL was observed to be identical in both IHD patients and normal subjects.
    • This indicates that LDL premodification within the bloodstream of IHD patients may facilitate subsequent modification after entering the vessel wall.

    Impact:

    • Provides insights into the biochemical alterations underlying IHD.
    • Suggests potential therapeutic targets related to LDL modification.
    • Highlights the importance of LDL's extracellular environment in cardiovascular disease development.

    More Related Videos

    Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

    Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

    Published on: November 10, 2017

    Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation06:47

    Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

    Published on: January 28, 2021

    Related Concept Videos

    Peroxisomes01:24

    Peroxisomes

    Peroxisomes are specialized organelles present in fungi, plant, and animal cells. It can vary in number, size, morphology, and activity depending on the type of tissue and the nutritional state of the cell. For example, cells with active lipid metabolism, such as adipocytes, neurons, and hepatocytes, have more peroxisomes than other cells in the body. Besides their primary role in breaking down complex organic molecules, peroxisomes can also synthesize specific macromolecules and participate in...
    Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents

    Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
    Ischemic Heart Disease: Overview01:17

    Ischemic Heart Disease: Overview

    Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
    Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
    Coronary Artery Disease II: Pathophysiology01:26

    Coronary Artery Disease II: Pathophysiology

    Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
    Coronary Artery Disease IV: Preventive Measures01:26

    Coronary Artery Disease IV: Preventive Measures

    Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
    Atherosclerosis III: Management01:26

    Atherosclerosis III: Management

    Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...